Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04228939
Other study ID # 78-17
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2019
Est. completion date July 31, 2021

Study information

Verified date January 2020
Source Ludwig-Maximilians - University of Munich
Contact Sandra Schlegl, PhD
Phone +4989440053369
Email sandra.schlegl@med.uni-muenchen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Inpatient treatment for patients with anorexia nervosa (AN) is recommended in extreme or severe cases after failure of outpatient treatment and is highly effective. However, a number of patients show symptom increase and relapse after discharge. The aim of this study is to evaluate the efficacy of a guided smartphone-based aftercare intervention following inpatient treatment of patients with AN to support symptom stabilization or continued improvement.


Description:

Anorexia nervosa (AN) is a severe, often chronic and life-threatening disorder. Relapse after treatment is common with relapse rates ranging between 9 and 52% and being highest within the first year following treatment particularly as early as 3 months posttreatment. Even if weight restoration is achieved, it is quite difficult for patients to sustain improvements after treatment, so aftercare and relapse prevention are essential research topics. There is a recent review on internet- and mobile-based aftercare and relapse prevention in mental disorders that concludes that there is some evidence that such interventions are feasible instruments for maintaining treatment gains for some mental disorders, including eating disorders (EDs). However, the authors claim for further high quality, large-scale trials that are needed to expand research fields. So, the aim of this study is to prove the efficacy of a guided smartphone-based aftercare intervention for inpatients with AN. Our primary hypothesis is that at the end of aftercare intervention (T1), the intervention group shows a significantly lower eating disorder symptomatology than the control group.

Eligible patients with AN who are discharged from inpatient treatment are randomized either to receive a 4-month smartphone-based aftercare intervention with therapist feedback as an add-on element to treatment as usual (TAU) or TAU alone. Assessments include structured interviews as well as online questionnaires and are taken at baseline (discharge, T0), end of the aftercare intervention (T1) as well as 6-month follow-up (T2).


Recruitment information / eligibility

Status Recruiting
Enrollment 184
Est. completion date July 31, 2021
Est. primary completion date January 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria:

- primary diagnosis of AN (DSM-5: 307.1),

- sex: female,

- age: from 12 years onwards to 60 years,

- regular completion of inpatient treatment,

- at least a length of inpatient stay of 6 weeks,

- BMI at discharge at least 15, at least a 1-point BMI increase during inpatient treatment,

- owner of a smartphone,

- informed consent of the patient and, in case of minors, also of the parents.

Exclusion Criteria:

- major depression (BDI-II > 29 at discharge),

- suicidal tendency (item 9 of BDI-II > 1 at discharge),

- very high level of care after inpatient treatment (e.g. therapeutic living community, day clinic),

- pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Recovery Record aftercare
Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of "Recovery Record" at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16.
Treatment as usual (TAU)
Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.

Locations

Country Name City State
Germany Schoen Clinic Roseneck Prien am Chiemsee

Sponsors (3)

Lead Sponsor Collaborator
Ludwig-Maximilians - University of Munich Schoen Clinic Roseneck, Swiss Anorexia Nervosa Foundation

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Eating Disorder Severity (assessor-based) The Eating Disorder Examination (EDE) will be used to measure asessor-based eating disorder symptom severity over time. Measured at baseline (discharge), at week 16 (end of treatment) and 6 month follow-up
Secondary Changes in Body-Mass-Index (BMI) Weight and height will be used to measure BMI over time. Measured at baseline, week 16 and 6 month follow-up
Secondary Changes in Eating Disorder Severity (self-report) The Eating Disorder Examination Questionnaire (EDE-Q) will be used to measure self-reported eating disorder symptom severity over time. Measured at baseline, week 16 and 6 month follow-up
Secondary Changes in depressive symptoms The Beck Depression Inventory-II (BDI-II) will be used to measure depressive symptoms over time. Measured at baseline, week 16 and 6 month follow-up
Secondary Changes in stages of change regarding specific eating disorder behaviors The Stages of Change Questionnaire for Eating Disorders (SOCQ-ED) will be used to measure changes in stages of change regarding specific eating disorder behaviors over time. Measured at baseline, week 16 and 6 month follow-up
Secondary Changes in self-efficay The General Self-Efficacy Scale (GSE) will be used to measure self-efficacy over time. Measured at baseline, week 16 and 6 month follow-up
Secondary Participant satisfaction with the app and the aftercare intervention A self-developed questionnaire will be used to assess self-reported satisfaction with the app and the aftercare intervention. Measured at week 16
Secondary Additional outpatient and inpatient treatment after discharge Number and length of outpatient or inpatient treatment (rehospitalization) since discharge will be assessed. Measured at week 16 and 6 month follow-up
Secondary Adherence to the smartphone-based aftercare intervention Adherence will be measured via dichotomous outcome of drop-out (individuals will be considered as drop-out if they fail to login to the app at all for a period of 14 consecutive days. Adherence will be assessed through application usage data. Measured from baseline to week 16
Secondary Adherence to self-monitoring tasks Frequency of self-monitoring entries will be tracked automatically through the program server Measured from baseline to week 16
See also
  Status Clinical Trial Phase
Recruiting NCT05531604 - Appetitive Conditioning in Anorexia Nervosa
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Active, not recruiting NCT04883554 - Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study N/A
Recruiting NCT04213820 - TMS and Body Image Treatment for Anorexia Nervosa N/A
Completed NCT03414112 - The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa Early Phase 1
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Recruiting NCT05803707 - Home-based Adapted Physical Activity in Anorexia Nervosa: a Feasibility Pilot Study N/A
Recruiting NCT05682417 - Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa N/A
Not yet recruiting NCT06380257 - Anorexia Nervosa and Brain in Adolescence
Not yet recruiting NCT04804800 - Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa N/A
Not yet recruiting NCT03600610 - Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa N/A
Completed NCT02745067 - Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa N/A
Completed NCT02382055 - Changing Habits in Anorexia Nervosa: Novel Treatment Development N/A
Terminated NCT02240797 - Kappa Opioid Receptor Imaging in Anorexia N/A
Completed NCT03075371 - Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa N/A
Unknown status NCT01761942 - Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Phase 2
Completed NCT03144986 - Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa N/A
Completed NCT01579682 - Adaptive Family Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT02551445 - A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders. N/A
Completed NCT00946816 - The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity N/A